Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. DMK Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2023 was $0.66 Mil. DMK Pharmaceuticals's Revenue for the
three
months ended in Sep. 2023 was $0.01 Mil.
DMK Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 73.72.
DMK Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023
declined
from Jun. 2023 (94.86) to Jun. 2023 (73.72)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
DMK Pharmaceuticals's Days Inventory for the
three
months ended in Sep. 2023 was 179.13.
Inventory Turnover measures how fast the company turns over its inventory within a year.
DMK Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2023 was 0.51.
DMK Pharmaceuticals Inventory-to-Revenue Historical Data
The historical data trend for DMK Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DMK Pharmaceuticals's Inventory-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DMK Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
DMK Pharmaceuticals's Days Inventory for the
three
months ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 